CVM · Cel Sci Corp
$1.54
+0.05 (+3.36%)
At close · Aug 14
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Due to recurring losses from operations and future liquidity needs, there is substantial doubt about the Company’s ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Market Cap
$27.09M
Shares
17.59M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.54
Open$1.52
Day$1.52–1.64
52W close$0.97–13.04
Avg vol 30d321K
Short int1.2M · 6.8% float · 3.8d
Short vol63%
DataMay 2025–Aug 2026
Filing10-Q · Aug 14
Raw chart and full-history price indicators begin at the captured split on May 20, 2025; bars on opposite sides are not compared.
Up next
FQ4-26 quarter ends
~Sep 30, 2026
Est
filed Aug 14, 2026
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 14.3 · calm
Equity put/call 0.52
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−59%
below
Price vs 50-day avg
+24%
above
RSI (14)
59
neutral
MACD trend
Positive
52-week position
5%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+32%
trailing
6-month return
−65%
trailing
YTD return
−71%
this year
Relative strength
−79%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.82% of float · ▲ +67.2% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
41 holders — mid 3-yr range
Squeeze score
70
high risk · 0–100
Fundamentals
Revenue growth
+65%
Y/Y
EPS growth
+59%
Y/Y
Free cash flow
$-17.2M
Balance sheet
$17.0M
net cash
Quant / Vol
risk profile
Volatility
113%
annualized · 1-yr
Max drawdown
−93%
past year
ATR
8.1%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−59%
Bearish
Price vs 50-day avg
+24%
Bullish
RSI (14)
59
Neutral
MACD trend
Positive
Bullish
52-week position
5%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
+5% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
6.82% of float · ▲ +67.2% MoM · 3.8 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
41 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 5%
Range high $13
vs 200-day avg -59%
vs 50-day avg +24%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CVM
this stock
Cel Sci Corp
|
$27.09M | -70.7% | +65.5% | — | 6.8% |
|
ONC
BeOne Medicines Ltd.
|
$513.62B | +14.4% | +22179.2% | 789.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$128.19B | +11.6% | +46.2% | 29.5 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$82.72B | +4.1% | +20.8% | 19.9 | 3.3% |
|
ARGX
Argenx SE
|
$52.94B | +1.2% | — | — | 2.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
Raw-price comparisons begin at the captured split on May 20, 2025; windows that need an earlier baseline remain unavailable.
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CVM | -10.5% | +31.6% | -65.4% | +32.8% | -70.7% |
| SPY | +0.4% | +4.5% | +13.8% | +3.9% | +13.9% |
| vs SPY | -10.9% | +27.2% | -79.2% | +28.8% | -84.6% |